Skip to main content
SpringerLink
Log in
Book cover

Diagnostic and Therapeutic Advances in Hematologic Malignancies pp 335–362Cite as

Advances in the therapy of the myelodysplastic syndromes

  • Chapter

Part of the book series: Cancer Treatment and Research ((CTAR,volume 99))

Abstract

The myelodysplastic syndrome (MDS) has been a most challenging disease for hematologists for decades. In terms of diagnosis, it was less than 20 years ago that the French-American-British (FAB) group developed criteria for the diagnosis and the classification of the myelodysplastic syndromes [1]. The FAB classification has provided a common language for hematologists, morphologists, and pathologists in the investigation of this clonal bone marrow disease, since, studies could be compared in part by stratifying patients into the appropriate MDS subgroup. Since its development, the FAB classification has led to countless studies — from kinder, gentler approaches using various vitamins in hopes of inducing differentiation of the MDS clone to ‘brute force’ approaches of high-dose therapy with allogeneic marrow rescue. This chapter will review therapeutic studies published in the past four years; readers interested in details of earlier studies can consult several references [2,3].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. 1982. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189–199.

    PubMed  CAS  Google Scholar 

  2. Kouides PA, Bennett JM. 1995. Myelodysplastic syndromes. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE (eds), Clinical Oncology. Churchill Livingstone: New York, pp 1977–1998.

    Google Scholar 

  3. Schumacher HR, Nand S. 1995. Myelodysplastic Syndromes: Approach to Diagnosis and Treatment. Igaku-Shoin: New York, pp 1–239.

    Google Scholar 

  4. Raza A, Gezer S, Mundle S, et al. 1995. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86:268–276.

    PubMed  CAS  Google Scholar 

  5. Raza A, Mundle S, Iftikhar A, et al. 1995. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Haematol 48:143–154.

    CAS  Google Scholar 

  6. Raza A, Mundle S, Shetty V, et al. 1996. A paradigm shift in myelodysplastic syndromes. Leukemia 10:1648–1652.

    PubMed  CAS  Google Scholar 

  7. Lepelley P, Campergue L, Grardel N, Preudhomme C, Cosson A, Fenaux P. 1996. Is apoptosis a massive process in myelodysplastic syndromes? Br J Haematol 95:368–371.

    PubMed  CAS  Google Scholar 

  8. Magill MK, Macfarlane E, McMullin MF. 1997. Intramedullary apoptosis may simply be a correlate of ineffective hematopoiesis. Br J Haematol 97(Suppl 1):17. (abstract)

    Google Scholar 

  9. Yoshida Y, Anzai N, Kawabata H. 1995. Apoptosis in myelodysplasia: a paradox or paradigm. Leuk Res 19:887–891.

    PubMed  CAS  Google Scholar 

  10. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. 1996. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 88:4275–4287.

    PubMed  CAS  Google Scholar 

  11. Mundle SD, Venugopal P, Cartlidge JD. 1996. Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood 88:2640–2647.

    PubMed  CAS  Google Scholar 

  12. Raza A, Shetty V, Dar S, Mundle S, Gregory S, Preisler H. 1997. Successful anti-cytokine based approach to treat Myelodysplastic Syndromes. Leuk Res 21(Suppl l):40. (abstract)

    Google Scholar 

  13. Nemunaitis J, Rosenfeld C, Getty L, Boegel F, Meyer W, Jennings LW, Zeigler Z, Shadduck R. 1995. Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial. Am J Clin Oncol 18:189–193.

    PubMed  CAS  Google Scholar 

  14. Boogaerts MA, Verhoef GE, Demuynck H. 1996. Treatment and prognostic factors in myelodysplastic syndromes (review). Baillieres Clin Haematol 9:161–183.

    PubMed  CAS  Google Scholar 

  15. Mufti GJ. 1992. A guide to risk assessment in the primary myelodysplastic syndrome (review with 128 refs). Haematol Oncol Clin North Am 6:587–606.

    CAS  Google Scholar 

  16. Greenberg P, Cox C, LeBeau MM, et al. 1997. International scoring system for evaluating prognosis in Myelodysplastic Syndromes. Blood 89:2079–2088.

    PubMed  CAS  Google Scholar 

  17. McCarley DL. 1993. New uses for old vitamins. The treatment of myelodysplastic disorders. Med Clin North Am 77:919–929.

    PubMed  CAS  Google Scholar 

  18. Morosetti R, Koeffler HP. 1996. Differentiation therapy in myelodysplastic syndromes. Semin Haematol 33:236–245.

    CAS  Google Scholar 

  19. Januszewicz EH, Firkin FC. 1988. Differentiation in acute myeloid leukemia and myelodysplastic disorders. Is differentiation-induction therapy possible? Aust N Z J Med 18:705–711.

    PubMed  CAS  Google Scholar 

  20. Clark RE, Jacobs A, Lush CJ, Smith SA. 1987. Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. Lancet 1:763–765.

    PubMed  CAS  Google Scholar 

  21. Letendre L, Levitt R, Pierre RV, Schroeder G, Krook JA, Mailliard JE, Morton RF, Tschetter LK. 1995. Myelodysplastic syndrome treatment with danazol and cis-retinoic acid. Am J Haematol 48:233–236.

    CAS  Google Scholar 

  22. Bourantas KL, Tsiara S, Christou L. 1995. Treatment of 34 patients with myelodysplastic syndromes with 13-CIS retinoic acid. Eur J Haematol 55:235–239.

    PubMed  CAS  Google Scholar 

  23. Ferrero D, Bruno B, Pregno P, et al. 1996. Combined differentiating therapy for myelodysplastic syndromes: a phase II study. Leuk Res 20:867–876.

    PubMed  CAS  Google Scholar 

  24. Kurzrock R, Estey E, Talpaz M. 1993. All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol 11:1489–1495.

    PubMed  CAS  Google Scholar 

  25. Ohno R, Naoe T, Hirano M, Kobayashi M, Hirai H, Tubaki K, Oh H. 1993. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare. Blood 81:1152–1154.

    PubMed  CAS  Google Scholar 

  26. Aul C, Runde V, Gattermann N. 1993. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. Blood 82:2967–2974.

    PubMed  CAS  Google Scholar 

  27. Visani G, Tosi P, Manfroi S, Ottaviani E, Finelli C, Cenacchi A, Bendandi M, Tura S. 1995. All-trans retinoic acid in the treatment of myelodysplastic syndromes. Leuk Lymphoma 19:277–280.

    PubMed  CAS  Google Scholar 

  28. Cambier N, Wattel E, Menot ML, Guerci A, Chomienne C, Fenaux P. 1996. All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study Leukemia 10:1164–1167.

    PubMed  CAS  Google Scholar 

  29. Viniou N, Micjali E, Meletis J, Andreopoulos A, Vaiopoulos G, Stavroyianni N, Loukopoulos D, Yataganas X. 1997. Trisomy 8 in a patient who responded to therapy with all-trans-retinoic acid and developed paroxysmal nocturnal hemoglobinuria. Br J Haematol 97:135–136.

    PubMed  CAS  Google Scholar 

  30. Ganser A, Seipelt G, Verbeek W, et al. 1994. Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia 8:369–375.

    PubMed  CAS  Google Scholar 

  31. Ganser A, Maurer A, Contzen C, et al. 1996. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-transretinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol. Ann Haematol 72:237–244.

    CAS  Google Scholar 

  32. Maurer AB, Ganser A, Seipelt G, Ottmann OG, Mentzel U, Geissler GR, Hoelzer D. 1995. Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors. Br J Haematol 89:449–456.

    PubMed  CAS  Google Scholar 

  33. Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, Ervin T, Kufe D, Rifkind RA, Marks PA. 1992. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 80:2604–2609.

    PubMed  CAS  Google Scholar 

  34. Rowinsky EK, Donehower RC, Spivak JL, Burke PJ, Griffin CA, Jones RJ. 1990. Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors. J Natl Cancer Inst 82:1926–1931.

    PubMed  CAS  Google Scholar 

  35. Petti MC, Latagliata R, Avvisati G, Spiriti MA, Montefusco E, Spadea A, Mandelli F. 1996. Treatment of high-risk myelodysplastic syndromes with lymphoblastoid alpha interferon. Br J Haematol 95:364–367.

    PubMed  CAS  Google Scholar 

  36. Motomura S, Fujisawa S, Tsunooka N, Fujimaki K, Mohri H, Okubo T. 1997. Hematologic benefits of 1-hydroxyvitamin D3 in an elderly patient with chronic myelodysplastic syndrome. Am J Haematol 53:143–144.

    Google Scholar 

  37. Silverman LR, Holland JF, Weinberg RS, et al. 1993. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7(Suppl l):21–29.

    PubMed  Google Scholar 

  38. Wijermans PW, Krulder JW, Huijgens PC, Neve P. 1997. Continuous infusion of low-dose 5-Aza-2’-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11:1–5.

    PubMed  CAS  Google Scholar 

  39. Zagonel V, Lo Re G, Marotta G, Babare R, Sardeo G, Gattei V, De Angelis V, Monfardini S, Pinto A. 1993. 5-Aza-2’-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 7(Suppl l):30–35.

    PubMed  Google Scholar 

  40. Pinto A, Zagonel V. 1993. 5-Aza-2’-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends (review). Leukemia 7(Suppl l):51–60.

    PubMed  Google Scholar 

  41. List A, Capizzi R, Heaton R, Glinsmann-Gibson B, Brasfield F, Taetle R, Schein P. 1997. Promotion of multilineage hematopoiesis in patients with Myelodysplastic Syndromes: a phase I/II clinical trial with Amifostine. Leuk Res 21(Suppl 1):47. (abstract)

    Google Scholar 

  42. Uhr M, Marini GL, Goldhirsch A, Cavalli F. 1997. Tamoxifen as a treatment for the Myelodysplastic Syndromes? A case report (abstract). Leuk Res 21(Suppl 1):43.

    Google Scholar 

  43. Vadhan-Raj S. 1997. Recombinant human hemoglobin for patients with anemia. Leukemia Insights Newsletter of the University of Texas M.D. Anderson Cancer Center 2:6.

    Google Scholar 

  44. Cheson BD, Jasperse DM, Simon R, Friedman MA. 1986. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 4:1857–1864.

    PubMed  CAS  Google Scholar 

  45. Kuriya S, Murai K, Miyairi Y, Utsugisawa T, Narigasawa Y, Ito T, Shimosegawa K, Ishida Y. 1996. A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study. Cancer 78:422–426.

    PubMed  CAS  Google Scholar 

  46. Munshi NC, Tricot GJ. 1997. Single weekly cytosine arabinoside and oral 6-thioguanine in patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Ann Haematol 74:111–115.

    CAS  Google Scholar 

  47. Im T, Yamane T, Mugitani A, Hiyoshi M, Park K, Tatsumi N. 1994. Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase. Int J Haematol 60:215–223.

    CAS  Google Scholar 

  48. Gerhartz HH, Zwierzina HH, Walther J, Fenaux P, Hayat M, Jacobs A, Hoffbrand AV, Dardenne M, Solbu G, Suciu S. 1996. Interleukin-3 plus low-dose cytosine arabinoside for advanced myelodysplasia: a pilot study. EORTC Leukemia Group. Cancer Invest 14:299–306.

    PubMed  CAS  Google Scholar 

  49. Juneja HS, Jodhani M, Gardner FH, Trevarthen D, Schottstedt M. 1994. Low-dose ARA-C consistently induces hematologic responses in the clinical 5q-syndrome. Am J Haematol 46:338–342.

    CAS  Google Scholar 

  50. Greenberg BR, Reynolds RD, Charron CB, Squillace KM, Lessin LS, Case DC Jr, Gams RA. 1993. Treatment of myelodysplastic syndromes with daily oral idarubicin. A phase I-II study. Cancer 71:1989–1992.

    PubMed  CAS  Google Scholar 

  51. Doll DC, Sun PC, List AF. 1994. Complete hematologic remission with oral etoposide in a patient with chronic myelomonocytic leukemia and profound dyserythropoiesis. Leuk Res 18:381–384.

    PubMed  CAS  Google Scholar 

  52. Ogata K, Nomura T. 1993. Application of low-dose etoposide therapy for myelodysplastic syndromes. Leuk Lymphoma 12:35–39.

    PubMed  CAS  Google Scholar 

  53. Wattel E, Guerci A, Hecquet B, et al. 1996. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood 88:2480–2487.

    PubMed  CAS  Google Scholar 

  54. Omoto E, Deguchi S, Takaba S, et al. 1996. Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. Leukemia 10:609–614.

    PubMed  CAS  Google Scholar 

  55. Kouides PA, Bennett JM. 1996. Morphology and classification of the myelodysplastic syndromes and their pathologic variants (review with 133 refs). Semin Haematol 33:95–110.

    CAS  Google Scholar 

  56. Ganser A, Heil G, Kolbe K, et al. 1993. Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia — initial results. Ann Haematol 66:123–125.

    CAS  Google Scholar 

  57. Economopoulos T, Papageorgiou E, Stathakis N, Constantinidou M, Parharidou A, Kostourou A, Dervenoulas J, Raptis S. 1996. Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor (GM-CSF). Leuk Res 20:385–390.

    PubMed  CAS  Google Scholar 

  58. Gassmann W, Schmitz N, Loffler H, De Witte T. 1996. Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Semin Haematol 33:196–205.

    CAS  Google Scholar 

  59. Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM, Schiffer CA, Bloomfield CD. 1996. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol 14:2486–2494.

    PubMed  CAS  Google Scholar 

  60. Ruutu T, Hanninen A, Jarventie G, et al. 1997. Intensive chemotherapy of poor prognosis Myelodysplastic Syndrome (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine. Leuk Res 21:133–138.

    PubMed  CAS  Google Scholar 

  61. Krieger OK, Girschikofsky M, Lang F, Oppitz P, Lutz D. 1997. Cladribine (20CDA) is active in ‘high-risk’ chronic myelomonocytic leukemia and secondary or relapsed acute myelo(mono)cytic leukemia. Leuk Res 21(Suppl 1):48.

    Google Scholar 

  62. Feldman EJ, Seiter KP, Ahmed T, Baskind P, Arlin ZA. 1996. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia 10:40–42.

    PubMed  CAS  Google Scholar 

  63. Beran M, Kantarjian H, O’Brien S, et al. 1996. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88:2473–2479.

    PubMed  CAS  Google Scholar 

  64. Anderson JE, Appelbaum FR, Fisher LD, et al. 1993. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82:677–681.

    PubMed  CAS  Google Scholar 

  65. Anderson JE, Appelbaum FR, Schoch G, et al. 1996. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 87:51–58.

    PubMed  CAS  Google Scholar 

  66. Sutton L, Chastang C, Ribaud P, et al. 1996. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood 88:358–365.

    PubMed  CAS  Google Scholar 

  67. Rapoport AP, DiPersio JF, Martin BA, et al. 1995. Patients > or = age 40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients < age 40 years. Bone Marrow Transplant 15:523–530.

    PubMed  CAS  Google Scholar 

  68. Ratanatharathorn V, Karanes C, Uberti J, et al. 1993. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 81: 2194–2199.

    PubMed  CAS  Google Scholar 

  69. O’Donnell MR, Long GD, Parker PM, et al. 1995. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 13:2973–2979.

    PubMed  CAS  Google Scholar 

  70. Castro-Malspina H, Childs B, Papadopoulos E, Boulad F, Young J, Small T, Kernan N, Collins N, O’Reilly R. 1997. T-cell depleted (SBA-E-) bone marrow transplantation for Myelodysplastic Syndromes. Leuk Res 21(Suppl 1):51. (abstract)

    Google Scholar 

  71. Tsuzuki M, Maruyama F, Kojima H, Ezaki K, Hirano M. 1995. Donor buffy coat infusions for a patient with myelodysplastic syndrome who relapsed following allogeneic bone marrow transplantation. Bone Marrow Transplant 16:487–489.

    PubMed  CAS  Google Scholar 

  72. Beguin Y, Collignon J, Laurent C, Fillet G. 1996. Spontaneous complete remission and recovery of donor haemopoiesis without GVHD after relapse and apparent marrow graft rejection in poor-prognosis myelodysplastic syndrome. Br J Haematol 94:507–509.

    PubMed  CAS  Google Scholar 

  73. Bressoud A, Chapuis B, Roux E, Cabrol C, Jeannet M, Roosnek E, Helg C. 1996. Donor lymphocyte infusion for a patient with relapsing myelodysplastic syndrome after allogeneic bone marrow transplantation. Blood 88:1902–1903. (letter)

    PubMed  CAS  Google Scholar 

  74. Schmitz N, Bacigalupo A, Labopin M, et al. 1996. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 95:715–723.

    PubMed  CAS  Google Scholar 

  75. Anderlini P, Pierce S, Kantarjian H, Estey E. 1996. Acute myeloid leukemia-type chemotherapy for myelodysplasia. J Clin Oncol 14:1404–1405. (letter)

    PubMed  CAS  Google Scholar 

  76. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F. 1991. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 77:497–501.

    PubMed  CAS  Google Scholar 

  77. Estey E. 1997. Treatment of myelodysplasia with AML type therapy vs. allogeneic bone marrow transplantation. Leukemia Insights Newsletter of the University of Texas M.D. Anderson Cancer Center 2:7.

    Google Scholar 

  78. Anderson JE, Anasetti C, Appelbaum FR, et al. 1996. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 93:59–67.

    PubMed  CAS  Google Scholar 

  79. Demuynck H, Verhoef GE, Zachee P, Emonds MP, van der Schueren E, Van den Berghe H, Vandenberghe P, Casteels-Van Daele M, Boogaerts MA. 1996. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant 17:745–751.

    PubMed  CAS  Google Scholar 

  80. Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J. 1996. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. Bone Marrow Transplantation 17:685–689.

    PubMed  CAS  Google Scholar 

  81. Laporte JP, Isnard F, Lesage S, Fenaux P, Douay L, Lopez M, Stachowiak J, Najman A, Gorin NC. 1993. Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): a pilot study. Leukemia 7:2030–2033.

    PubMed  CAS  Google Scholar 

  82. Demuynck H, Delforge M, Verhoef GE, Zachee P, Vandenberghe P, Van den Berghe H, Boogaerts MA. 1996. Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol 92:351–359.

    PubMed  CAS  Google Scholar 

  83. Delforge M, Demuynck H, Vandenberghe P, Verhoef G, Zachee P, van Duppen V, Marijnen P, Van den Berghe H, Boogaerts MA. 1995. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood 86:3660–3667.

    PubMed  CAS  Google Scholar 

  84. Ganser A, Hoelzer D. 1996. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes (review with 95 refs). Semin Haematol 33:186–195.

    CAS  Google Scholar 

  85. Rose C, Wattel E, Bastion Y, Berger E, Bauters F, Coiffier B, Fenaux P. 1994. Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases. Leukemia 8:1458–1462.

    PubMed  CAS  Google Scholar 

  86. Schuster MW, Thompson JA, Larson R, Allen SL, O’Laughlin R, Israel R, Fefer A. 1990. Randomized trial of subcutaneous granulocyte-macrophage colony stimulating factor versus observation in patients with Myelodysplastic Syndrome or Aplastic Anemia. Proc Am Soc Clin Oncol 9:205. (abstract)

    Google Scholar 

  87. Greenberg P, Taylor K, Koeffler P, et al. 1993. Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes. Blood 82(Suppl 1):196. (abstract)

    Google Scholar 

  88. Chiba S, Inamori K, Mitani K, Hirai H, Yazaki Y. 1994. Marked and reproducible increase in trilineage blood cell counts by administration of granulocyte colony-stimulating factor in a patient with refractory anaemia with excess blasts in transformation. Br J Haematol 86:665–667.

    PubMed  CAS  Google Scholar 

  89. Perugini O, Montanari G, Nalli G. 1995. Trilineage response to granulocyte colony-stimulating factor administration in a patient with myelodysplastic syndrome. Haemato logica 80:234–237.

    CAS  Google Scholar 

  90. Takahashi M, Yoshida Y, Kaku K, Masaoka T, Moriyama Y, Nakanishi S, Kaneko T, Shibata A, Miwa S. 1993. Phase II study of recombinant human granulocyte-macrophage colony-stimulating factor in myelodysplastic syndrome and aplastic anemia. Acta Haematol 89:189–194.

    PubMed  CAS  Google Scholar 

  91. Hellstrom-Lindberg E. 1995. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 89:67–71.

    PubMed  CAS  Google Scholar 

  92. Hellstrom-Lindberg E, Birgegard G, Carlsson M, et al. 1993. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymphoma 11:221–228.

    PubMed  CAS  Google Scholar 

  93. Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, Greenberg PL. 1993. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82:737–743.

    PubMed  CAS  Google Scholar 

  94. Takahashi M, Aoki A, Mito M, Nikkuni K, Ohtsuka T, Saitoh H, Moriyama Y, Shibata A. 1993. Combination therapy with rhGM-CSF and rhEpo for two patients with refractory anemia and aplastic anemia. Haematol Pathol 7:153–158.

    CAS  Google Scholar 

  95. Hansen PB, Johnsen HE, Hippe E, Hellstrom-Lindberg E, Ralfkiaer E. 1993. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes. Am J Haematol 44:229–236.

    CAS  Google Scholar 

  96. Bernell P, Stenke L, Wallvik J, Hippe E, Hast R. 1996. A sequential erythropoietin and GM-CSF schedule offers clinical benefits in the treatment of anaemia in myelodysplastic syndromes. Leuk Res 20:693–699.

    PubMed  CAS  Google Scholar 

  97. Stenke L, Wallvik J, Celsing F, Hast R. 1993. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia 7:1324–1327.

    PubMed  CAS  Google Scholar 

  98. Di Raimondo F, Longo G, Cacciola E Jr, Milone G, Palumbo GA, Cacciola RR, Alessi M, Giustolisi R. 1996. A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study. Eur J Haematol 56:7–11.

    PubMed  Google Scholar 

  99. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L. 1995. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 89:831–837.

    PubMed  CAS  Google Scholar 

  100. Razzano M, Caslini C, Cortelazzo S, Battistel V, Rambaldi A, Barbui T. 1993. Clinical and biological effects of erythropoietin treatment of myelodysplastic syndrome. Leuk Lymphoma 10:127–134.

    PubMed  CAS  Google Scholar 

  101. Ghio R, Balleari E, Ballestrero A, Gatti AM, Mareni C, Massa G, Patrone F, Sessarego M, Timitilli S. 1993. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes. Acta Haematol 90:58–64.

    PubMed  CAS  Google Scholar 

  102. Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, Novella A, Rovati A, Bergamaschi G, Beguin Y. 1996. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 81:434–441.

    PubMed  CAS  Google Scholar 

  103. Musto P, Scalzulli PR, Carotenuto M. 1995. Recombinant erythropoietin for myelodysplastic syndromes. Br J Haematol 91:256–258. (letter)

    PubMed  CAS  Google Scholar 

  104. Bowen DT, Culligan D, Beguin Y, Kendall R, Willis N. 1994. Estimation of effective and total erythropoiesis in myelodysplasia using serum transferrin receptor and erythropoietin concentrations, with automated reticulocyte parameters. Leukemia 8:151–155.

    PubMed  CAS  Google Scholar 

  105. Musto P, Modoni S, Alicino G, et al. 1994. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes. Haematologica 79: 493–499.

    PubMed  CAS  Google Scholar 

  106. Hoefsloot LH, Vanamelsvoort MP, Breeders LCAM, Vanderplas DC, Vanlom K, Hoogerbrugge H, Touw IP, Lowenberg B. 1997. Erythropoietin-induced activation of STAT5 is impaired in the Myelodysplastic Syndrome. Blood 89:1690–1700.

    PubMed  CAS  Google Scholar 

  107. Ganser A, Seipelt G, Lindemann A, et al. 1990. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76:455–462.

    PubMed  CAS  Google Scholar 

  108. Kurzrock R, Talpaz M, Estrov Z, Rosenblum MG, Gutterman JU. 1991. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9:1241–1250.

    PubMed  CAS  Google Scholar 

  109. Bowen D, Yancik S, Bennett L, Culligan D, Resser K. 1993. Serum stem cell factor concentration in patients with myelodysplastic syndromes. Br J Haematol 85:63–66.

    PubMed  CAS  Google Scholar 

  110. Zwierzina H, Bammer T, Rollingerholzinger I, Herold M, Fenaux P, Nussler V, Hoeflehner E, Geissler D. 1997. In vitro stimulation of erythropoiesis by stem cell factor alone in Myelodysplastic Syndrome patients with elevated endogenous erythropoietin serum levels. Clin Cancer Res 2:1031–1038.

    Google Scholar 

  111. Masters GS, Baines P, Tang C, Bowen D, Burnett AK. 1995. Responsiveness to stem cell factor (SCF) of peripheral blood colony-forming cells from patients with myelodysplastic syndromes (MDS). Leuk Res 19:561–566.

    PubMed  CAS  Google Scholar 

  112. Wu HK, Chiba S, Hirai H, Takaku F, Yazaki Y. 1994. Effect of stem cell factor (c-kit ligand) on clonogenic leukemic precursor cells: synergy with other hematopoietic growth factors. Am J Haematol 47:328–330.

    CAS  Google Scholar 

  113. Gordon MS, Nemunaitis J, Hoffman R, Paquette RL, Rosenfeld C, Manfreda S, Isaacs R, Nimer SD. 1995. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 85:3066–3076.

    PubMed  CAS  Google Scholar 

  114. Kunishima S, Tahara T, Kato T, Kobayashi S, Saito H, Naoe T. 1996. Serum thrombopoietin and plasma glycocalicin concentrations as useful diagnostic markers in thrombocytopenic disorders. Eur J Haematol 57:68–71.

    PubMed  CAS  Google Scholar 

  115. Chabannon C, Molina L, Pegourie-Bandelier B, Bost M, Leger J, Hollard D. 1994. A review of 76 patients with myelodysplastic syndromes treated with danazol. Cancer 73:3073–3080.

    PubMed  CAS  Google Scholar 

  116. Wattel E, Cambier N, Caulier MT, Sautiere D, Bauters F, Fenaux P. 1994. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases. Br J Haematol 87:205–208.

    PubMed  CAS  Google Scholar 

  117. Hebbar M, Kaplan C, Caulier MT, Wattel E, Morel P, Wetterwald M, Bauters F, Fenaux P. 1996. Low incidence of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy. Br J Haematol 94:112–115.

    PubMed  CAS  Google Scholar 

  118. Stadtmauer EA, Cassileth PA, Edelstein M, Abrahm J, Schreiber AD, Nowell PC, Cines DB. 1991. Danazol treatment of myelodysplastic syndromes. Br J Haematol 77:502–508.

    PubMed  CAS  Google Scholar 

  119. Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T, Boesen AM, Ellegaard J. 1996. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 94:288–299.

    PubMed  CAS  Google Scholar 

  120. Holcombe RF. 1993. Mini-dose interferon alpha-2a in the treatment of myelodysplasia. Leukemia 7:192–195.

    PubMed  CAS  Google Scholar 

  121. Stone RM, Spriggs DR, Arthur KA, Mayer RJ, Griffin J, Kufe DW. 1993. Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes. Am J Clin Oncol 16:159–163.

    PubMed  CAS  Google Scholar 

  122. Ogata K, Yokose N, Nomura T. 1995. Interleukin-2 therapy for myelodysplastic syndrome: does it work? Leuk Lymphoma 17:411–415.

    PubMed  CAS  Google Scholar 

  123. Rosenfeld CS, Zeigler ZR, Shadduck RK, Nilsson B. 1997. Phase II study of roquinimex in Myelodysplastic Syndrome. Am J Clin Oncol 20:189–192.

    PubMed  CAS  Google Scholar 

  124. Biesma DH, Vandentweel JG, Verdonck LF. 1997. Immunosuppressive therapy for hypoplastic Myelodysplastic Syndrome. Cancer 79:1548–1551.

    PubMed  CAS  Google Scholar 

  125. Ogata K, Yokose N, Ito T, An E, Tamura H, Dan K, Hamaguchi H, Sakamaki H, Onozawa Y, Nomura T. 1994. Assessment of therapeutic potential of interleukin 2 for myelodysplastic syndromes. Br J Haematol 86:562–567.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Peter A. Kouides
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John M. Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northwestern University Medical School, Chicago, Illinois, USA

    Martin S. Tallman M.D.  & Leo I. Gordon M.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Kluwer Academic Publishers, Boston

About this chapter

Cite this chapter

Kouides, P.A., Bennett, J.M. (1999). Advances in the therapy of the myelodysplastic syndromes. In: Tallman, M.S., Gordon, L.I. (eds) Diagnostic and Therapeutic Advances in Hematologic Malignancies. Cancer Treatment and Research, vol 99. Springer, Boston, MA. https://doi.org/10.1007/978-0-585-38571-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-0-585-38571-6_14

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-7923-8206-5

  • Online ISBN: 978-0-585-38571-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation